Document Detail


Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma.
MedLine Citation:
PMID:  21428906     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Asthma is a complex disease characterized by variable airflow limitation, hyperresponsiveness, and airways inflammation. Despite valuable therapeutic advances to control asthma symptoms in the last decade, a quantifiable proportion of patients with moderate to severe asthma continue to experience inadequate disease control, highlighting an important unmet need. In animal models of asthma, interleukin (IL)-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways. Mast cells are involved in the pathogenesis of eosinophilic and noneosinophilic asthma. Thus, targeting the IL-9 pathway may provide a new therapeutic modality for asthma. The purpose of this review is to summarize the IL-9-mast cell axis in the pathogenesis of asthma and discuss clinical studies with a humanized anti-IL-9 monoclonal antibody, MEDI-528, in subjects with asthma.
Authors:
Chad K Oh; Donald Raible; Gregory P Geba; Nestor A Molfino
Related Documents :
10679786 - Oligodendrocytes and the control of myelination in vivo: new insights from the rat ante...
18438416 - Cd3-specific antibody-induced immune tolerance involves transforming growth factor-beta...
16848686 - Fatalities in natalizumab treatment--a 'no go' for leukocyte recirculation approaches?
9532586 - The cytokine storm in multiple sclerosis.
2649866 - The neonatal human's immune response to herpes simplex virus infection: a critical review.
15712606 - Cytokine and chemokine expression in the central nervous system associated with protect...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Inflammation & allergy drug targets     Volume:  10     ISSN:  2212-4055     ISO Abbreviation:  Inflamm Allergy Drug Targets     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-05-03     Completed Date:  2011-09-08     Revised Date:  2011-11-10    
Medline Journal Info:
Nlm Unique ID:  101266886     Medline TA:  Inflamm Allergy Drug Targets     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  180-6     Citation Subset:  IM    
Affiliation:
MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA. molfinon@medimmune.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / pharmacology
Asthma / immunology*,  physiopathology,  therapy*
Clinical Trials as Topic
Disease Models, Animal
Humans
Immunotherapy*
Interleukin-9 / antagonists & inhibitors,  immunology*
Mast Cells / immunology*
Th1-Th2 Balance / drug effects
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Interleukin-9; 0/MEDI-528

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Immunologic diseases and brain tumors.
Next Document:  Nasal polyposis: from pathogenesis to treatment, an update.